Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $64.9 million.

  • Summit Therapeutics' Total Current Liabilities rose 1003.07% to $64.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.9 million, marking a year-over-year increase of 1003.07%. This contributed to the annual value of $41.7 million for FY2024, which is 10450.38% up from last year.
  • Per Summit Therapeutics' latest filing, its Total Current Liabilities stood at $64.9 million for Q3 2025, which was up 1003.07% from $60.3 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Total Current Liabilities peaked at $140.2 million during Q2 2024, and registered a low of $11.9 million during Q2 2023.
  • Moreover, its 5-year median value for Total Current Liabilities was $25.6 million (2021), whereas its average is $43.4 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 6889.34% in 2022, then skyrocketed by 107482.19% in 2024.
  • Summit Therapeutics' Total Current Liabilities (Quarter) stood at $25.6 million in 2021, then soared by 51.36% to $38.8 million in 2022, then tumbled by 47.39% to $20.4 million in 2023, then surged by 104.5% to $41.7 million in 2024, then surged by 55.59% to $64.9 million in 2025.
  • Its Total Current Liabilities stands at $64.9 million for Q3 2025, versus $60.3 million for Q2 2025 and $34.9 million for Q1 2025.